RxDoctor Payments Data

Zachary Meyer, MD

Family Medicine · Grand Island, NENPI 1649408428

Payments from drug & device makers

$2,328in general payments, 2019–2025

Across 180 payments — averaging $12.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$994
  • Novo Nordisk$183
  • Lilly USA, LLC$136
  • Sanofi-aventis U.S. LLC$131
  • Abbott$113
  • Amarin Pharma, Inc.$106
  • plus $667 from 20 others

What the payments were for

  • Food & beverage$2,31699%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,328 in reported general payments places this provider in the 75th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$131,709
Medicare patients
207
Services billed
4,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$106,604
MounjaroTirzepatide51$73,724
EliquisApixaban63$70,613
TrulicityDulaglutide36$52,268
JardianceEmpagliflozin59$50,887
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$44,489
LinzessLinaclotide45$34,006
FarxigaDapagliflozin Propanediol29$29,782
XareltoRivaroxaban52$26,284
Soliqua 100-33Insulin Glargine/Lixisenatide18$23,446
ArexvyRsvpref3 Antigen/As01e/Pf53$16,655
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$15,990
ShingrixVaricella-Zoster Ge/As01b/Pf51$11,282
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$6,629
Nebivolol Hcl128$6,114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$136$125,99287 claims
Novo NordiskOzempic$183$106,60461 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$43$72,426165 claims
PfizerEliquis$48$70,61363 claims
AstraZenecaFarxiga, Breztri Aerosphere$81$45,77348 claims
AbbVieLinzess$994$34,00645 claims
Johnson & JohnsonXarelto$31$26,28452 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$131$23,44618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Grand Island

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →